These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19477882)

  • 1. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
    Yasui-Furukori N; Saito M; Nakagami T; Furukori H; Suzuki A; Kondo T; Kaneko S
    J Psychopharmacol; 2010 Jul; 24(7):987-94. PubMed ID: 19477882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
    Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sugawara N; Fujii A; Kaneko S
    J Clin Psychopharmacol; 2011 Oct; 31(5):633-7. PubMed ID: 21869689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
    Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
    J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
    Yoshimura R; Shinkai K; Ueda N; Nakamura J
    Pharmacopsychiatry; 2007 Jan; 40(1):9-13. PubMed ID: 17327954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy.
    Klampfl K; Taurines R; Preuss A; Burger R; Rothenhöfer S; Wewetzer Ch; Pfuhlmann B; Fegert J; Gerlach M; Mehler-Wex C
    Pharmacopsychiatry; 2010 Mar; 43(2):58-65. PubMed ID: 20336598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
    Spina E; Avenoso A; Facciolà G; Salemi M; Scordo MG; Ancione M; Madia AG; Perucca E
    Psychopharmacology (Berl); 2001 Jan; 153(2):238-43. PubMed ID: 11205425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risperidone in the treatment of acute exacerbation of schizophrenia symptoms].
    Gutiérrez M; Gibert J; Bobes J; Herráiz ML; Fernández A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(2):83-9. PubMed ID: 9595821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDR1 gene polymorphisms and response to acute risperidone treatment.
    Kastelic M; Koprivsek J; Plesnicar BK; Serretti A; Mandelli L; Locatelli I; Grabnar I; Dolzan V
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):387-92. PubMed ID: 20060871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.
    Yoshimura R; Hori H; Sugita A; Ueda N; Kakihara S; Umene W; Nakano Y; Shinkai K; Mitoma M; Ohta M; Shinkai T; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1072-7. PubMed ID: 17459549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
    Henderson DC; Goff DC
    J Clin Psychiatry; 1996 Sep; 57(9):395-7. PubMed ID: 9746446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone plasma levels, clinical response and side-effects.
    Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone].
    Sannomiya M; Katsu H; Nakayama K
    Seishin Shinkeigaku Zasshi; 2003; 105(5):643-58. PubMed ID: 12875232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
    Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
    Yasui-Furukori N; Saito M; Nakagami T; Kaneda A; Tateishi T; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):286-91. PubMed ID: 16386826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection.
    Aravagiri M; Marder SR; Wirshing D; Wirshing WC
    Pharmacopsychiatry; 1998 May; 31(3):102-9. PubMed ID: 9657237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term relapse prevention with risperidone in 215 schizophrenic patients].
    Udina Abelló C; Roca Bennasar M; Octavio Del Valle I
    Actas Esp Psiquiatr; 2001; 29(4):243-9. PubMed ID: 11470059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.